Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2012 2
2013 2
2014 1
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

5 results
Results by year
Filters applied: . Clear all
Page 1
Recent developments with live-attenuated recombinant paramyxovirus vaccines.
Le Bayon JC, Lina B, Rosa-Calatrava M, Boivin G. Le Bayon JC, et al. Rev Med Virol. 2013 Jan;23(1):15-34. doi: 10.1002/rmv.1717. Epub 2012 May 8. Rev Med Virol. 2013. PMID: 22570186 Review.
There is no vaccine currently approved for paramyxovirus-induced respiratory diseases in humans, despite their major clinical importance. We review the development and evaluation of new vaccine strategies based on live-attenuated chimeric …
There is no vaccine currently approved for paramyxovirus-induced respiratory diseases in humans, despite their major clinical …
Evaluation of synthetic infection-enhancing lipopeptides as adjuvants for a live-attenuated canine distemper virus vaccine administered intra-nasally to ferrets.
Nguyen DT, Ludlow M, van Amerongen G, de Vries RD, Yüksel S, Verburgh RJ, Osterhaus AD, Duprex WP, de Swart RL. Nguyen DT, et al. Vaccine. 2012 Jul 20;30(34):5073-80. doi: 10.1016/j.vaccine.2012.05.079. Epub 2012 Jun 21. Vaccine. 2012. PMID: 22705079
For measles and canine distemper virus (CDV) safe and effective live-attenuated virus vaccines are available, but for human respiratory syncytial virus and human metapneumovirus development of such vaccines has proven difficult. We …
For measles and canine distemper virus (CDV) safe and effective live-attenuated virus vaccines are available, but for …
Roles of the putative integrin-binding motif of the human metapneumovirus fusion (f) protein in cell-cell fusion, viral infectivity, and pathogenesis.
Wei Y, Zhang Y, Cai H, Mirza AM, Iorio RM, Peeples ME, Niewiesk S, Li J. Wei Y, et al. J Virol. 2014 Apr;88(8):4338-52. doi: 10.1128/JVI.03491-13. Epub 2014 Jan 29. J Virol. 2014. PMID: 24478423 Free PMC article.
Human metapneumovirus (hMPV) is a relatively recently identified paramyxovirus that causes acute upper and lower respiratory tract infection. ...Our results also identify the integrin-binding motif to be a new, attenuating target for the development of
Human metapneumovirus (hMPV) is a relatively recently identified paramyxovirus that causes acute upper and lower respir
A target site for template-based design of measles virus entry inhibitors.
Plemper RK, Erlandson KJ, Lakdawala AS, Sun A, Prussia A, Boonsombat J, Aki-Sener E, Yalcin I, Yildiz I, Temiz-Arpaci O, Tekiner B, Liotta DC, Snyder JP, Compans RW. Plemper RK, et al. Proc Natl Acad Sci U S A. 2004 Apr 13;101(15):5628-33. doi: 10.1073/pnas.0308520101. Epub 2004 Mar 31. Proc Natl Acad Sci U S A. 2004. PMID: 15056763 Free PMC article.
Measles virus (MV) constitutes a principal cause of worldwide mortality, accounting for almost 1 million deaths annually. Although a live-attenuated vaccine protects against MV, vaccination efficiency of young infants is low because of interference by …
Measles virus (MV) constitutes a principal cause of worldwide mortality, accounting for almost 1 million deaths annually. Although a live
Infection-enhancing lipopeptides do not improve intranasal immunization of cotton rats with a delta-G candidate live-attenuated human respiratory syncytial virus vaccine.
Tien Nguyen D, Boes J, van Amerongen G, van Remmerden Y, Yüksel S, Guichelaar T, Osterhaus AD, de Swart RL. Tien Nguyen D, et al. Hum Vaccin Immunother. 2013 Dec;9(12):2578-83. doi: 10.4161/hv.26096. Epub 2013 Aug 16. Hum Vaccin Immunother. 2013. PMID: 23955280 Free PMC article.
Development of live-attenuated human respiratory syncytial virus (HRSV) vaccines has proven to be difficult. ...We hypothesized that these lipopeptides can be used as adjuvants to promote immune responses induced by live-attenuated
Development of live-attenuated human respiratory syncytial virus (HRSV) vaccines has proven to be difficu